Dexmedetomidine an Effective Drug in Reducing Anesthetic Requirements in External Dacrocystorhinostomy (DCR) Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Dexmedetomidine Hydrochloride.
- Who it may be relevant to
- Registry conditions: Patients Undergoing External Dacrocystorhinostomy Operations, Assess Decreased Anesthetic Requirements Intraoperative. Basic parameters: 16 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Dexmedetomidine As an Effective Drug in Reducing Anesthetic Requirements in Patients Undergoing External Dacrocystorhinostomy, a Randomized Controlled Study
Overview
Assessing the intra and postoperative hemodynamic stability in patients undergoing external dacrocystorhinostomy under general anesthesia using Dexmedetomidine as a preoperative sedation compared to traditional technique with intraoperative analgesia and assessing decreased anesthetic requirements intra and postoperative
Detailed description
Dexmedetomidine is a highly selective alpha 2 adrenoceptor agonist, having characteristics of natural sleep like sedation, can reduce pain intensity and opioid consumption without influencing the time of recovery from general anesthesia
Interventions
- Drug Dexmedetomidine Hydrochloride
drug will be given before induction and anesthetic doses and hemodynamics will be assessed pre- intra and postoperative
Primary outcome measures
- Maintained hemodynamic values while reducing the anesthetic requirements [Time frame: from 20 minutes after administering the drug till 2 hours after full recovery]
Secondary outcome measures (1)
- Delerium [Time frame: from 20 minutes after administering the drug till 2 hours after full recovery]
Eligibility criteria
Inclusion criteria
patients of both sexes 16 years to 75 years of age ASA (American society of Anesthesiologists) I-III
Exclusion criteria
- Pediatric age group
- ASA more than III
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Other
Study locations
Egypt · 1 center
- Research Institute of Ophthalmolgy — Giza
Identifiers
NCT: NCT06808295 · 24-11-17-6-5